• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Protara Therapeutics Inc. (Amendment)

    2/14/24 7:11:45 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARA alert in real time by email
    SC 13G/A 1 ss3005745_sc13ga.htm AMENDMENT NO. 2
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Protara Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

     

     

    74365U107
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
       

     

     

    CUSIP No. 74365U107  SCHEDULE 13G Page 2 of 7 Pages

     

             
    1

    NAME OF REPORTING PERSONS

    OrbiMed Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA

     

     

     

       

     

     

    CUSIP No. 74365U107  SCHEDULE 13G Page 3 of 7 Pages

     

             
    1

    NAME OF REPORTING PERSONS

    OrbiMed Advisors LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA

     

     

     

     

       

     

     

    CUSIP No.  74365U107  SCHEDULE 13G Page 4 of 7 Pages

     

    Item 1.   (a) Name of Issuer:

    Protara Therapeutics, Inc.

        (b) Address of Issuer’s Principal Executive Offices:

    345 Park Ave. South, Third Floor

    New York, NY 10010

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital LLC

    OrbiMed Advisors LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on each cover page for each Reporting Person.

        (d) Title of Class of Securities:

    Common Stock, $0.001 par value per share

        (e) CUSIP No.:

    74365U107

     

     

     

     

     

       

     

     

    CUSIP No. 74365U107  SCHEDULE 13G Page 5 of 7 Pages

     

     

    Item 3.      

    OrbiMed Advisors LLC and OrbiMed Capital LLC are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 74365U107  SCHEDULE 13G Page 6 of 7 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9. Notice of Dissolution of Group.

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 74365U107  SCHEDULE 13G Page 7 of 7 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

           
      OrbiMed Advisors LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member

     

           
      OrbiMed Capital LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $TARA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TARA

    DatePrice TargetRatingAnalyst
    4/16/2025$12.00Sector Outperform
    Scotiabank
    3/14/2025Overweight
    Cantor Fitzgerald
    7/10/2023$22.00Buy
    Guggenheim
    11/8/2021$32.00 → $34.00Outperform
    Oppenheimer
    More analyst ratings

    $TARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Shefferman Jesse gifted 18,667 shares, decreasing direct ownership by 2% to 959,886 units (SEC Form 4)

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      6/30/25 4:10:10 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sargen Gregory

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      6/13/25 4:05:27 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Levy Richard S

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      6/13/25 4:05:20 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    SEC Filings

    See more
    • Protara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Protara Therapeutics, Inc. (0001359931) (Filer)

      6/12/25 4:17:51 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

      SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

      5/14/25 12:13:54 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

      SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

      5/12/25 9:01:36 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Protara Therapeutics with a new price target

      Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

      4/16/25 8:13:38 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Protara Therapeutics

      Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight

      3/14/25 7:42:48 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim resumed coverage on Protara Therapeutics with a new price target

      Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00

      7/10/23 7:28:47 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

      4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

      5/19/25 4:10:10 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

      4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

      5/16/25 4:05:07 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Leadership Updates

    Live Leadership Updates

    See more
    • Protara Therapeutics Announces Addition to the Russell 3000® Index

      NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid

      6/30/25 8:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

      NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

      6/2/25 4:04:01 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

      NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. "We are delighted to welcome Dr. Nicacio to the Protara team," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "As a proven leader with deep expertise spanning all stages of drug development, his guida

      4/15/25 4:13:42 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Financials

    Live finance-specific insights

    See more
    • Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

      TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patientsFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsOn track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company

      4/26/25 10:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2

      4/23/25 8:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

      TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at

      12/5/24 7:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Protara Therapeutics Inc.

      SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

      12/17/24 4:02:03 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Protara Therapeutics Inc.

      SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

      11/18/24 6:01:42 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Protara Therapeutics Inc.

      SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

      11/14/24 1:00:40 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 29,500 stock option awards and 14,750 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on July 1, 202

      7/1/25 4:12:07 PM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in its Fourth Venture Fund

      Continues Successful Strategy of Discovering and Investing in Breakthrough Biomedical Technologies Around the Globe Catalio Capital Management, LP ("Catalio"), a leading innovative healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV ("Fund IV" or the "Fund"), with over $400M in commitments across the Fund and its related co-investment vehicles. The Fund received significant backing from current Catalio investors as well as new, global institutional investors, RIAs, foundations and endowments. The fundraise marks a significant milestone for Catalio, reinforcing investor confidence in its differentiated strategy of backing bre

      7/1/25 9:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protara Therapeutics Announces Addition to the Russell 3000® Index

      NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid

      6/30/25 8:00:00 AM ET
      $TARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care